RUNX1 isoform imbalance drives ML-DS, VWF-binding RNA aptamer for hemophilia A treatment, and EZH1/2 inhibitor valemetostat in relapsed/refractory ATL
Blood Podcast
00:00
A Review of Run Daptovon-Pegel in Hemophilia A
Treatment with run Daptovon-Pegel was well tolerated. There were no specific drug-related events, no serious adverse events and no thrombotic events. Some bleeding was observed during the current trial but none of the events were thought to be related to run Daptovsky treatment. Although these results are promising, larger and longer studies are needed to fully characterize the therapeutic potential in hemophilia A.
Transcript
Play full episode
